Press Releases
Published: July 07, 2020

Propeller Health sensor to be co-packaged with recently approved Enerzair® Breezhaler® asthma medication in Europe

Enerzair® Breezhaler® plus sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform

MADISON, Wisc., July 7, 2020 – Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.

This collaboration marks the first time a digital health tool will be packaged and prescribed alongside an inhaled asthma medication. Enerzair® Breezhaler® and Propeller sensor and app received approval from the European Commission in July and will launch across Europe starting in 2020. Healthcare professionals in Europe will have the option to prescribe Enerzair® Breezhaler® with or without the companion digital health platform. The medication is not available in the U.S.

Enerzair® Breezhaler® was approved as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.

Propeller’s solution works by attaching a sensor to the Enerzair® Breezhaler® inhaler, which then delivers objective data on medication use to the Propeller app on the patient’s smartphone. The app also sends the patient reminders to take their prescribed dose and keeps a record of adherence data over time. The patient can share that data with their clinician to help inform the patient’s treatment plan.

In previous clinical studies unrelated to this collaboration, the Propeller platform has been shown to increase asthma control by up to 63 percent,1 increase medication adherence by up to 58 percent,2 and reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent.3

“Our collaboration with Novartis to co-package Propeller with Enerzair® Breezhaler® is the first time a pharmaceutical company and digital health company have worked together to package a digital health platform with an asthma medication,” said David Van Sickle, co-founder and CEO of Propeller Health. “The ability to prescribe a maintenance medication with Propeller will make it easier for healthcare professionals to engage their patients in self-management.”

Propeller previously announced a collaboration with Novartis to develop a custom add-on sensor for the Breezhaler® inhaler, a device used for the company’s portfolio of COPD treatments (Ultibro® Breezhaler®, Onbrez® Breezhaler® and Seebri® Breezhaler®), connecting these medications to Propeller’s digital health platform. The same sensor will be co-packaged with Enerzair® Breezhaler®.

1 Merchant RK et al. J Allergy Clin Immunol Pract 2016
2 Van Sickle D et al. Eur Respir J 2016
3 Merchant RK et al. World Allergy Org J 2018

About Propeller Health
Propeller Health is a leading digital health company dedicated to making life better for every person with chronic respiratory disease. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit http://www.propellerhealth.com.

You Might Also Like

Propeller Health Named a Winner of Fierce Healthcare Innovation Awards 2022

Propeller Health’s precision digital health platform wins the Clinical Information Management category of the Fierce Healthcare Innovation Awards 2022. The platform enables physicians and care teams to proactively identify at-risk patients in between routine visits and provide more timely clinical interventions.

MADISON, WI, November 15, 2022 – Propeller Health, a leader in precision digital health, today announces its platform for chronic condition management is a Fierce Healthcare Innovation Awards 2022 winner. The program showcases outstanding innovation that is driving improvements and transforming the industry. The Propeller Digital Health Platform for Chronic Condition Management (The Propeller Platform”) enables proactive clinical care by collecting objective patient data and displaying resulting insights directly within a provider’s native workflow. 

At Propeller, data itself is only the beginning – activating it is what powers patient care,” said Susa Monacelli, Propeller Health General Manager. By surfacing the data within clinicians' existing workflow through EHR integrations, we enable their treatment decisions and help identify at-risk patients. Patient self-management coupled with proactive clinician intervention helps improve clinical outcomes and, in turn, economic value for health systems, payers, and patients. Our focus is to do this across connected medications and therapies to change healthcare at scale.”

Propeller Health accelerates push towards value-based care with new digital health solutions for patients, providers and health systems

Announces integrations with multiple leading Electronic Health Record (EHR) systems, introduces a new solution to enable Remote Therapeutic Monitoring (RTM) by healthcare providers, and launches digital platform updates to enable respiratory care at home, in-clinic, and on-the-go.

MIAMI, March 7, 2022 – Propeller Health, a leader in digital health for asthma and chronic obstructive pulmonary disease (COPD), today announced three exciting updates and new solutions to bring its clinically proven, FDA-cleared platform to more patients, providers and health systems.

Integrations expand the reach of Propeller’s digital platform to more health systems
Propeller Health research shows digital health programs help improve outcomes for vulnerable and underserved populations with chronic respiratory conditions
News Announcement at HLTH 2021, Boston MA, October 18, 2021 MADISON, Wisconsin, October 18, 2021 - Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), revealed two recent studies that showed that digital health interventions alongside appropriate care resources and tools can expand access and improve outcomes for elderly and underserved populations. Propeller’s digital health platform includes Bluetooth® connected inhaler sensors that chime medication reminders and record inhaler medication use, paired with a smartphone app that provides education and feedback to support self-management. In a study1 conducted in partnership with Desert Oasis Healthcare, Propeller evaluated the effect of digital health intervention on healthcare resource utilization and medication use in patients with COPD. 56 patients with COPD, average age 75, were enrolled by their clinical pharmacists, who received alerts through Propeller’s clinician portal whenever patients showed low controller medication adherence or high rescue inhaler use.